# Binding Capacity and Adsorption Stability of Uremic Metabolites to Albumin-Modified Magnetic Nanoparticles

**Authors:** Indu Sharma, Agatha Milley, Lun Zhang, Jiamin Zheng, Ethan Lockwood, David S. Wishart, Marcello Tonelli, Larry D. Unsworth

PMC · DOI: 10.3390/ijms26115366 · 2025-06-03

## TL;DR

Researchers tested albumin-coated magnetic nanoparticles for their ability to bind and remove harmful uremic metabolites from blood, which could improve dialysis for kidney disease patients.

## Contribution

The study demonstrates that albumin-modified nanoparticles can effectively adsorb uremic metabolites with improved efficiency and specificity compared to unmodified controls.

## Key findings

- Albumin-modified nanoparticles showed higher metabolite adsorption efficiency than unmodified controls.
- Adsorption selectivity and stability were influenced by albumin concentration and incubation time.
- The results suggest potential for developing advanced blood purification materials for dialysis.

## Abstract

Kidney disease causes the retention of uremic metabolites in blood, which is associated with many comorbidities. Hemodialysis does not properly clear many metabolites, including large, middle-sized, and small protein-bound uremic toxins (PBUTs). Adsorption strategies for metabolite removal require the development of engineered adsorbents with tailored surfaces to increase the binding of desired metabolites. Albumin is uniquely positioned for modifying blood-contacting surfaces to absorb uremic metabolites, as it (i) minimizes non-specific protein adsorption and (ii) binds a range of molecules at Sudlow Sites I and II with different affinities. It is unknown if albumin-modified surfaces retain the adsorption qualities of solution-free albumin, namely, adsorption stability or specificity. Herein, albumin was covalently attached to iron oxide nanoparticles and characterized using multiple methods. Metabolite adsorption was conducted by incubating particles in a model solution of thirty-three uremic metabolites associated with kidney failure. Adsorption efficiency, selectivity, and stability were affected by albumin concentration and incubation time. Metabolite adsorption was found to change with time, and it was more effective on albumin-modified particles than unmodified controls. The findings outlined in this paper are crucial for the design of next-generation advanced blood-contacting materials to enhance dialysis and blood purification for patients with kidney disease.

## Linked entities

- **Proteins:** LOC100189571 (uncharacterized LOC100189571)
- **Diseases:** kidney disease (MONDO:0001343)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** kidney failure (MESH:D051437), Kidney disease (MESH:D007674), Uremic (MESH:D006463)
- **Chemicals:** iron oxide (MESH:C000499), uremic (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12155526/full.md

---
Source: https://tomesphere.com/paper/PMC12155526